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Integrating patient reported outcome measures (PROMs) into randomised controlled trials 
(RCTs) has gained momentum during the past few decades1. However, there is little uniformity in 
the way that these outcomes are handled. Various research groups exist to develop methods of 
reducing the variation in outcome measures2 and some have applied this to prostate cancer 
research3 but few have then explored how these PROMs are implemented and analysed.  
 
Review question 
This scoping review aims to capture (1) which PROMs are being used in prostate research, (2) 
when they are collected after treatment commencement and (3) how they are then being 
analysed. The review will focus on statistical analysis techniques used as well as the placement 






We aim to identify RCT papers, in the PubMed4 database, that are based on prostate RCTs (e.g. 
treatments for prostate cancer or lower urinary tract symptoms in men) and include at least one 
PROM as an outcome. The search for relevant papers is restricted to those published between 
1st of January 2011 and 31st December 2020 to capture recent activity, in the use of PROMs, and 
avoid difficulties in retrieving electronic copies.  
 
The search will be restricted to the top 5 medical journals, the top 5 urology journals and top 5 
oncology journals, with highest impact factors in 20155, that return at least 1 matching article 
(Table 1). 
 
Table 1. The journals included, based on impact factors in 2015 
InCites Journal Citation Reports (2015)5, ranked by Impact Factor 
Top “medical” journals  
 
Ret. Top “urology” journals*  Ret. Top “oncology” journals Ret. 
New England Journal of 
Medicine  
P European Urology  P CA-A Cancer Journal for 
Clinicians  
O 
The Lancet  P Nature Reviews Urology O Nature Reviews Cancer O 
Journal of American Medical 
Association  
P Journal of Urology  P Lancet Oncology  P 
The BMJ  P BJU International  P Cancer Cell O 




Journal of Clinical Oncology  P 
 
  The Prostate  P Cancer Discovery  P 
    Nature Reviews Clinical 
Oncology  
O 
    Leukemia  O 
    Journal of the National Cancer 
Institute  
P 
    Seminars in Cancer Biology  O 
    Annals of Oncology  P 
Ret. = Returned at least one matching article from the search, *Within the category Urology & Nephrology 
 





Table 2. The search criteria that will be used for data extraction 
Resource (date) Search terms Years (incl.) Papers 
PubMed4 
(12/07/21) 
((prostat*[Title/Abstract]) OR ((lower urinary tract[Title/Abstract]) AND 
(men[Title/Abstract]))) AND ((patient-reported[Title/Abstract]) OR (patient 
reported[Title/Abstract]) OR (quality of life[Title/Abstract]) OR (self-
report*[Title/Abstract]) OR (symptom score[Title/Abstract])) AND 
((random*[Title/Abstract]) OR (trial[Title/Abstract])) AND (("N Engl J 
Med"[Journal]) OR ("JAMA"[Journal]) OR ("BMJ"[Journal]) OR 
("Lancet"[Journal]) OR ("Annals of internal medicine"[Journal]) OR 
("European urology"[Journal]) OR ("The Journal of urology"[Journal]) OR 
("BJU international"[Journal]) OR ("Prostate cancer and prostatic 
diseases"[Journal]) OR ("The Prostate"[Journal]) OR ("The Lancet. 
Oncology"[Journal]) OR ("Cancer cell"[Journal]) OR ("J Clin 
Oncol"[Journal]) OR ("Cancer discovery"[Journal]) OR ("Journal of the 
National Cancer Institute"[Journal]) OR (""annals of oncology official 







Stages of review 
Initially titles will be screened, by the primary researcher, to exclude; protocols, reviews, 
responses to authors, etc. Abstracts will then be inspected separately, by the primary researcher 
and an independent reviewer, to exclude any other articles that do not fulfil the inclusion criteria. 
Full text articles will then be read by the primary researcher to identify the final list of eligible 
articles. For the first 10 full text reviews, the independent reviewer will also carry out a full text 
review to ensure that the eligibility criteria is clear and unambiguous. The level of agreement will 
be reported and the eligibility criteria altered, if required. A proforma, consisting of eligibility 
criteria will be defined in advance of article extraction.  
 





























Records identified through 
database searching 
(n =   ) 
Additional records identified 
through other sources 
(n =   ) 
Titles screened 
(n =   ) 
Abstracts screened 
(n =   ) 
Abstracts excluded 
(n =   ) 
Full-text articles 
assessed for eligibility 
(n =   ) 
Full-text articles excluded 
(n =   ) 
Studies included in 
qualitative synthesis 





One reviewer, two 
reviewers for a sample 
Titles excluded 




The inclusion criteria are RCT articles that report PROM findings in men receiving active or 
placebo/sham treatment, for conditions of the prostate. The minimum number of patients 
recruited in the trial has to be at least 50 men, randomised to 2-4 arms, in a parallel group 
design. Where multiple papers have been published, analysing the same dataset, they will all be 
included at the point of extraction. Longitudinal PROMs are the key items of interest, however, 
the used of single measure ‘static’ PROMs will be quantified. Health economic findings, reviews, 
protocols and methodological papers, including published statistical analysis plans, will be 
excluded from this extract. However, despite being excluded, they may be referred back to if any 




The key items, to answer the objectives, are the specific PROM used, where they included it in 
the treatment pathway and the statistical analysis performed on the PROM. For each article the 
following items will be identified: the condition which is being treated, the intervention(s) of 
interest, the number of men, the length of follow up, the specific PROMs used, when they were 
included in the treatment pathway, whether they were static or transitional and how they were 
analysed. Analyses will be scrutinised to determine the statistical method used, the handling of 
missing data, the handling of loss to follow up (e.g. death) and analysis grouping (e.g. intention 
to treat). If time allows, this review will also assess how adjuvant treatments/therapies were 
accounted for. There are no plans to carry out a risk of bias review or to carry out a meta-
analysis, given that this is a review of trial design and statistical methods, rather than an 
exhaustive review of a specific outcome. The team aims to publish this review in 2022. 
 
 
Review team members, their organisation and role in this review 
Ms Grace Young, University of Bristol, UK 
Primary researcher who will be conducting the review at all stages 
Professor Athene Lane, University of Bristol, UK 
Overseeing the research; assisting with clinical trial design and PROMs 
Mr Hugo Pedder, University of Bristol, UK 
Overseeing the research; assisting with the overall review 
Ms Eleanor Walsh, University of Bristol, UK 
Independent researcher who will be screening the abstracts 
Professor Chris Metcalfe, University of Bristol, UK 
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